Recent Research Funding

Faculty secure several million dollars annually for their research from various public and private sources, including the National Institutes of Health, U.S. Food and Drug Administration, National Multiple Sclerosis Society, foundations and pharmaceutical firms.

  • A phase 3 double-blind study to evaluate the efficacy and safety of oral ozanimod compared to oral fingolimod in children and adolescents with relapsing-remitting multiple sclerosis. Michael Dwyer, III (Co-Investigator). Bristol Myers Squibb. $1,649,376. 6/1/2023-12/1/2032.
  • Clinical and Translational Science Award. Core Operations Special Populations. Ralph Benedict (Co-Investigator). NIH. $29,204,726. 1/1/2025-12/1/2031.
  • MRI-Based Quantitative Mapping of Oxygen Extraction Fraction in MS. Ferdinand Schweser (Co-Investigator). NIBIB. $1,773,283. 4/1/2024-3/1/2029.
  • Prepare the mind: Can coaching in goal-directed behaviour increase the success of cognitive rehabilitation in people with MS?. Ralph Benedict (Consultant). National MS Foundation. 10/1/2024-9/1/2028.
  • Investigation of behavioral and neural indices of multisensory information processing in Multiple Sclerosis: A novel approach. Exploration -hypothesis development award. David Shucard (Co-Investigator). Department of Defense Multiple Sclerosis Research Program. $232,022. 3/1/2025-3/1/2027.
  • Internet Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis. Ralph Benedict (Co-Investigator). NIH. $2,536,000. 9/1/2021-11/1/2026.
  • Clinical, Genetic, and Cellular Consequences of Mutations in NA, K-ATPASE ATP1A3. Ralph Benedict (Co-Investigator). NIH. 12/1/2021-11/1/2026.
  • Mapping complex dynamics in natural networks. Thomas Covey (Co-Principal Investigator). National Science Foundation. $32,000. 10/1/2024-10/1/2026.
  • Innovative methods for enhancing cognitive rehabilitation and promoting neural recovery in people with multiple sclerosis. Thomas Covey (Principal Investigator). UB Neuroscience Program Pilot Grant. $25,000. 8/1/2025-8/1/2026.
  • Normalization of Multinational BICAMS Data: A Retrospective Regression-Based Analysis. Ralph Benedict (Principal Investigator). Sanofi SA. $266,000. 4/1/2025-8/1/2026.
  • Clinical, Genetic, and Cellular Consequences of Mutations in Na, K-ATP1A3. Allison Brashear (Principal Investigator). NINDS. $8,808,869. 4/1/2008-6/1/2026.
  • Lung-brain coupling and the immune response to acute ischemic stroke. Marc Halterman (Principal Investigator). NIH/NINDS. 5/1/2021-6/1/2026.
  • Optimizing Chest Compressions Targeting Gas Exchange and Hemodynamics in a Transitional Cardiac Arrest Model. Ferdinand Schweser (Co-Investigator). National Institutes of Health. $1,642,389. 4/1/2021-3/1/2026.
  • A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients. Bianca Weinstock-Guttman (Principal Investigator). Tiziana Therapeutics. $110,000. 1/1/2025-2/1/2026.
  • Investigation of the neural underpinnings of declining driving performance in aging adults. Thomas Covey (Principal Investigator). UB CTSI, NCATS. $42,000. 1/1/2025-1/1/2026.
  • Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS) - Observational Participants. Bianca Weinstock-Guttman (Principal Investigator). PCORI. 1/1/2020-12/1/2025.
  • Cerebral Protection in Transcatheter Aortic Valve Replacement: The PROTEMBO Trial. Michael Dwyer, III (Co-Investigator). Protembis GmbH. $992,994. 6/1/2023-12/1/2025.
  • Neural indices of cognitive decline and cognitive resiliency in people with neurological disturbances. Thomas Covey (Principal Investigator). National Institutes of Health. $28,321. 10/1/2023-10/1/2025.
  • Investigation of behavioral and neural indices of multisensory information processing in Multiple Sclerosis: A novel approach. Thomas Covey (Principal Investigator). Department of Defense Multiple Sclerosis Research Program. $232,022. 9/1/2021-9/1/2025.
  • Evaluation of patient-reported outcomes associated with use of natalizumab in a real-world setting. Bianca Weinstock-Guttman (Principal Investigator). Biogen. $124,000. 1/1/2020-7/1/2025.